Thalia Therapeutics (LON:THAT) Posts Earnings Results

by · The Markets Daily

Thalia Therapeutics (LON:THAT – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported GBX (0.09) EPS for the quarter, Digital Look Earnings reports.

Thalia Therapeutics Stock Performance

LON THAT opened at GBX 0.61 on Wednesday. Thalia Therapeutics has a twelve month low of GBX 0.40 and a twelve month high of GBX 0.95. The company has a market cap of £10.89 million and a price-to-earnings ratio of -3.61.

Thalia Therapeutics Company Profile

(Get Free Report)

Thalia Therapeutics plc is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.

RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.

Further Reading